The Tarragona Association Against Cancer has invested part of the funds from its 2023 Research Grants programme in a project of the IISPV’s Radiotherapy Oncology Research Group to research cancer and to contribute to increasing the average survival rate of cancer sufferers to 70% by 2030 (another of its key objectives).
The Association Against Cancer in Tarragona helped to fund a project led by IISPV researcher Raquel García with a budget of 140,000 euros. This project (with a duration of four years) is focused on creating a model to predict the response of metastases treated with radiotherapy using imaging tests and blood markers, with the ultimate goal of being able to personalise treatments for each patient and improve their quality of life and survival in the disease.
Specifically, this project will study which patients with metastases may respond best to SABR (stereotactic ablative radiotherapy), which is a very precise type of radiotherapy in which high doses of radiation are delivered to the tumour while protecting the surrounding healthy organs as much as possible.
The research will also use artificial intelligence to combine the results of imaging tests with the results of each patient’s blood tests, so that a personalised predictive model can be created for each cancer patient with metastases who will receive SABR.
At the award ceremony for the 2023 Research Grants, Dr Raquel García said: “Our project consists of developing a model that allows us to predict how patients with different types of cancer and metastases will respond to ablative stereotactic radiotherapy sessions; it is very precise and delivers high doses of radiation while protecting the surrounding healthy organs”.
Facebook 
Mail 
WhatsApp